Cambridge Cognition Launches Aqua Automated Quality Assurance Solution
Mixture to be used for central nervous system clinical trials.
Cambridge Cognition announced that it has officially launched Aqua, its automated quality assurance solution for central nervous system (CNS) clinical trials. Powered by the company’s winterlight speech and language platform, the solution is the first product of its kind to be available on the market.
“Aqua is an entirely new solution for the clinical trials market providing a level of quality assurance that was not possible before, from a cost or time perspective, with traditional reviews by medical experts,” said Matthew Stork, CEO, Cambridge Cognition. “We acquired Winterlight Labs intending to commercialize their innovative verbal clinical assessments and, by launching Aqua, we have achieved the first of our product goals. We are also really pleased to have already won a client for Aqua as we expect this will provide us with an excellent case study for future sales.”
Reference: Launch of automated quality assurance for clinical trials. Cambridge Cognition. October 24, 2023. Accessed October 25, 2023. https://cambridgecognition.com/launch-of-automated-quality-assurance-for-clinical-trials/
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
